Evidence map›Paper›PMID 39876972›Full record

ReviewArchives of endocrinology and metabolism2024

Pyriproxyfen, villain or good guy? A brief review.

Andressa Pereira Cabral, Fabrício Pereira Dos Santos Maia, D'Angelo Carlo Magliano, Jones Bernardes Graceli, Paula Soares, Eduardo Andrés Rios Morris, Leandro Miranda-Alves

Abstract readReview
In one paragraph

Review in Archives of endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Basic and translational endocrinology.Archives of endocrinology and metabolism · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Andressa Pereira CabralUniversidade Federal do Rio de Janeiro Instituto de Ciências Biomédicas Laboratório de Endocrinologia Experimental Rio de JaneiroRJ Brasil Laboratório de Endocrinologia Experimental (LEEx), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.ORCID https://orcid.org/0000-0002-4526-6959
Fabrício Pereira Dos Santos MaiaUniversidade Federal do Rio de Janeiro Instituto de Ciências Biomédicas Laboratório de Endocrinologia Experimental Rio de JaneiroRJ Brasil Laboratório de Endocrinologia Experimental (LEEx), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.ORCID https://orcid.org/0009-0009-3869-1445
D'Angelo Carlo MaglianoUniversidade Federal Fluminense Centro de Morfologia e Metabolismo NiteróiRJ Brasil Centro de Morfologia e Metabolismo, Universidade Federal Fluminense, Niterói, RJ, Brasil.ORCID https://orcid.org/0000-0002-0575-961X
Jones Bernardes GraceliUniversidade Federal do Espírito Santo Laboratório de Endocrinologia e Toxicologia Celular Departamento de Morfologia Espírito SantoES Brasil Laboratório de Endocrinologia e Toxicologia Celular, Departamento de Morfologia, Universidade Federal do Espírito Santo, Espírito Santo, ES, Brasil.ORCID https://orcid.org/0000-0001-9349-4369
Paula SoaresUniversidade do Porto Instituto de Investigação e Inovação em Saúde Grupo de Sinalização e Metabolismo Celular Porto Portugal Grupo de Sinalização e Metabolismo Celular, i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal.ORCID https://orcid.org/0000-0001-9607-6998
Eduardo Andrés Rios MorrisUniversidade Federal do Rio de Janeiro Programa de Pós-graduação em Endocrinologia Faculdade de Medicina Rio de JaneiroRJ Brasil Programa de Pós-graduação em Endocrinologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.ORCID https://orcid.org/0000-0002-8504-3805
Leandro Miranda-AlvesUniversidade Federal do Rio de Janeiro Instituto de Ciências Biomédicas Laboratório de Endocrinologia Experimental Rio de JaneiroRJ Brasil Laboratório de Endocrinologia Experimental (LEEx), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.ORCID https://orcid.org/0000-0001-7832-8717

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pyriproxyfen (PPF) acts as a juvenile growth regulator, interfering with normal metamorphosis and blocking the development of insects into adulthood. Although the World Health Organization (WHO) considers the use of PPF at a concentration of 0.01 mg/L as unlikely to pose health risks, recent studies have unveiled potential risks associated with PPF exposure to non-target organisms. Exposure to PPF disrupts insect development primarily by mimicking juvenile hormones; therefore, concerns linger over its impact on unintended species. Studies have highlighted the adverse effects of PPF on aquatic invertebrates, fish, and amphibians and revealed mortality and developmental abnormalities in non-target mosquito species exposed to PPF-treated water. Moreover, PPF may act as an endocrine disruptor, interfering with hormonal pathways crucial for growth, reproduction, and behavior in exposed organisms. Amphibians, for instance, display altered reproductive physiology and developmental abnormalities due to disruptions in endocrine signaling pathways caused by PPF. The ecological ramifications of PPF extend beyond direct toxicity to non-target species. Indirect effects include shifts in food web dynamics and ecosystem functioning. Reductions in insect populations, induced by PPF, can disrupt food availability for higher trophic levels, potentially destabilizing community structure and ecosystem equilibrium. Given mounting evidence of unintended consequences, robust risk assessment and regulatory oversight are imperative. Accurate classification of PPF by regulatory bodies is essential to balancing its role in disease control and pest management benefits with the need to safeguard non-target species and maintain ecosystem health. Future research must prioritize comprehensive assessments of PPF's ecological impact across various habitats and taxa to inform evidence-based policymaking.

Indexed as

Endocrine DisruptorsInsecticidesPyridinesAnimalsHumansJuvenile HormonesEndocrine DisruptorsInsecticidesJuvenile HormonesPyridinespyriproxyfenendocrine disruptorPyriproxyfentoxic effects

Identifiers

PMID39876972
PMCPMC11771759

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.